{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"50"}],"units":"Participants"}],"description":"Number of patients who developed chronic extensive GVHD post-transplant. The diagnosis of chronic GVHD requires at least one manifestation that is distinctive for chronic GVHD as opposed to acute GVHD. In all cases, infection and others causes must be ruled out in the differential diagnosis of chronic GVHD.","groups":[{"description":"Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.\n\nfludarabine phosphate: Given IV\n\ntotal-body irradiation: Undergo radiotherapy\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Arm I (Nonmyeloablative Conditioning With Fludarabine and TBI)"},{"description":"Patients undergo TBI on day 0. All patients then undergo allogeneic peripheral blood stem cell transplantation on day 0 and receive tacrolimus PO every 12 hours on days -3 to 180, with taper on day 56, or tacrolimus IV if unable to tolerate PO; and mycophenolate mofetil PO every 12 hours on days 0-27 or mycophenolate mofetil IV if unable to tolerate PO.\n\ntotal-body irradiation: Undergo radiotherapy\n\nmycophenolate mofetil: Given IV or PO\n\ntacrolimus: Given IV or PO\n\nperipheral blood stem cell transplantation: Undergo allogeneic peripheral blood stem cell transplant\n\nnonmyeloablative allogeneic hematopoietic stem cell transplantation: Undergo allogeneic peripheral blood stem cell transplant\n\nlaboratory biomarker analysis: Correlative studies","id":"OG001","title":"Arm II (Nonmyeloablative Conditioning With TBI)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Day 180 post-transplantation","title":"Incidence of Chronic Extensive GVHD","type":"PRIMARY","unitOfMeasure":"Participants"}